MedTrace Logo

Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH

NCT02893826 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2018-07-26

No results posted yet for this study

Summary

Safety and Pharmacokinetic study comparing intracisternal EG-1962 to enternal nimopidine in the treatment of aneurysmal subarachnoid hemorrhage.

Conditions

  • Subarachnoid Hemorrhage, Aneurysmal

Interventions

DRUG

EG-1962 (nimodipine microparticles)

DRUG

Enteral Nimodipine

Sponsors & Collaborators

  • Edge Therapeutics Inc

    lead INDUSTRY

Principal Investigators

  • R. Loch Macdonald, MD, PhD · Edge Therapeutics Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-12-31
Completion
2018-03-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02893826 on ClinicalTrials.gov